We are live on ! Find out more
SIOX

Sio Gene Therapies Inc. Common Stock
SIOX

Delisted

SIOX was delisted on the 22nd of March, 2023.

Back to rankings

114 hedge funds and large institutions have $718M invested in Sio Gene Therapies Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 48 increasing their positions, 20 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 20

3% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 29

1% more funds holding

Funds holding: 113 → 114 (+1)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

47% less call options, than puts

Call options by funds: $40.5M | Put options by funds: $75.9M

72% less capital invested

Capital invested by funds: $2.52B → $718M (-$1.8B)

Holders
114
Holders Change
+1
Holders Change %
+0.88%
% of All Funds
2.84%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
30
Increased
48
Reduced
20
Closed
29
Calls
$40.5M
Puts
$75.9M
Net Calls
-$35.4M
Net Calls Change
-$66M

Top Buyers

Rank Fund Capital Flow
1
PC
PointState Capital
New York
+$41.6M
2
SCM
Sio Capital Management
New York
+$23.6M
3
Citadel Advisors
Citadel Advisors
Florida
+$20.8M
4
IPLA
Ice Pond Lane Advisers
New York
+$20.3M
5
DM
Deerfield Management
New York
+$17.1M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$84.5M
2
Capital Research Global Investors
Capital Research Global Investors
California
-$80.1M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$47.9M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$34M
5
CCM
Camber Capital Management
Massachusetts
-$23.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$1.34M +$4.1M +24,313 New
Ameriprise
27
Ameriprise
Minnesota
$1.33M +$3.45M +20,463 +560%
Vanguard Group
28
Vanguard Group
Pennsylvania
$1.24M +$187K +1,106 +5%
AFG
29
American Financial Group
Ohio
$1.19M – – –
AQR Capital Management
30
AQR Capital Management
Connecticut
$1.14M +$2.45M +14,552 +235%
Geode Capital Management
31
Geode Capital Management
Massachusetts
$1.07M +$2.15M +12,746 +188%
HCMT
32
Highland Capital Management (Texas)
Texas
$1.03M +$3.16M +18,750 New
Morgan Stanley
33
Morgan Stanley
New York
$879K +$712K +4,222 +36%
Citigroup
34
Citigroup
New York
$854K -$2.07M -12,282 -44%
TCIM
35
TIAA CREF Investment Management
New York
$825K +$786K +4,662 +45%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$748K +$130K +771 +6%
AA
37
ALPS Advisors
Colorado
$729K +$217K +1,288 +11%
GTC
38
Ghost Tree Capital
New York
$688K -$1.58M -9,375 -43%
Parallax Volatility Advisers
39
Parallax Volatility Advisers
California
$633K +$1.94M +11,503 New
CWG
40
C WorldWide Group
Denmark
$550K -$1.09M -6,438 -39%
VMI
41
VHCP Management II
New York
$524K -$4.76M -28,195 -75%
FO
42
FT Options
Illinois
$514K +$1.37M +8,108 +661%
D.E. Shaw & Co
43
D.E. Shaw & Co
New York
$513K -$34M -201,593 -96%
ARTA
44
A.R.T. Advisors
New York
$509K +$544K +3,225 +53%
CS
45
Candriam SCA
Luxembourg
$475K -$506K -3,000 -26%
Balyasny Asset Management
46
Balyasny Asset Management
Illinois
$420K +$1.29M +7,625 New
Charles Schwab
47
Charles Schwab
California
$400K +$175K +1,038 +17%
TA
48
Teachers Advisors
New York
$369K -$10.6K -63 -0.9%
Swiss National Bank
49
Swiss National Bank
Switzerland
$369K – – –
Wells Fargo
50
Wells Fargo
California
$369K +$652K +3,863 +136%
1
2
3 4 5

SIOX Hedge Fund Activity: Q3 2017 in Review

114 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q3 2017, worth a combined $718M — down 72% from $2.52B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new SIOX positions and 29 closed out — a net gain of 1 holder — while 48 added to existing stakes and 20 trimmed.

The largest buyer was PointState Capital, adding an estimated $41.6M. The largest seller was Fidelity Investments, cutting an estimated $84.5M.

  • 114 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q3 2017, up from 113 in Q2 2017.
  • Funds reported $718M of Sio Gene Therapies Inc. Common Stock stock for Q3 2017, down 72% quarter-over-quarter.
  • 30 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q3 2017 and 29 closed out, a net change of +1 holder.
  • The largest Sio Gene Therapies Inc. Common Stock buyer in Q3 2017 was PointState Capital, an estimated $41.6M added.
  • The largest Sio Gene Therapies Inc. Common Stock seller in Q3 2017 was Fidelity Investments, an estimated $84.5M sold.

Based on aggregated 13F filings for Q3 2017.